KEYNOTE-024 — Pembrolizumab Versus Platinum-Based Chemotherapy in Metastatic NSCLC With PD-L1 >=50%

Phase 3 · 2016 · Non-Small Cell Lung Cancer

Design

Randomized pembrolizumab monotherapy vs platinum-based chemotherapy, with crossover permitted.

Population

Untreated metastatic NSCLC with PD-L1 tumor proportion score >=50% and no EGFR/ALK alterations.

Primary Endpoint

progression-free survival (PFS)

Key Result

PFS 10.3 vs 6.0 mo (HR 0.50); OS HR 0.63, median OS 30.0 vs 14.2 mo.

Guideline Impact

NCCN category 1 first-line pembrolizumab monotherapy for PD-L1 >=50% NSCLC